Glenmark Pharmaceuticals share news and announcements
NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap
Last close ₹2,166.60down ₹31.90 (1.45%)BSE ₹2,129.60
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,198.50.
52-week range of traded prices to 23 Oct 2026
₹1,792.60Low, 28 Oct 2025₹2,537.60High, 28 Aug 2026
- Next results date: the board meets on 5 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹61,147 Cr176th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 31 Jul 2026
- 34.0
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 16.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 5.8
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.12%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 31 Jul 2026
- 18.6%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,943 crore of one-off items, the largest of them in the quarter to Sep 2025.
- 38.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 31 Jul 2026
- 39.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 8,92,79752.3% delivered
Glenmark Pharmaceuticals analyst meets
70 filed, newest first. Page 1 of 2.
Oct 2026
23 Oct · Analysts
Sep 2026
21 Sep · Analysts
Aug 2026
7 Aug · Analysts
Jul 2026
21 Jul · Analysts
Jun 2026
25 Jun · Analysts
May 2026
29 May · Analysts
23 May · Analysts
Feb 2026
2 Feb · Analysts
Jan 2026
22 Jan · Analysts
Nov 2025
14 Nov · Analysts
6 Nov · Analysts
Sep 2025
8 Sep · Analysts
Aug 2025
28 Aug · Analysts
14 Aug · Analysts
8 Aug · Analysts
Jul 2025
10 Jul · Analysts
May 2025
19 May · Analysts
Feb 2025
27 Feb · Analysts
17 Feb · Analysts
5 Feb · Analysts
Nov 2024
6 Nov · Analysts
Sep 2024
17 Sep · Analysts
Aug 2024
5 Aug · Analysts
May 2024
31 May · Analysts
File name: “Investordacy_Transcript”
17 May · Analysts
15 May · Analysts
Feb 2024
19 Feb · Analysts
2 Feb · Analysts
Nov 2023
16 Nov · Analysts
6 Nov · Analysts
Sep 2023
22 Sep · Analysts
Aug 2023
4 Aug · Analysts
May 2023
10 May · Analysts
Jan 2023
17 Jan · Analysts
Nov 2022
Sep 2022
Aug 2022
May 2022
Feb 2022
13 Feb · Analysts
3 Feb · Analysts
Nov 2021
3 Nov · Analysts
Aug 2021
May 2021